International Journal of Clinical Case Reports, 2025, Vol.15, No.6, 271-282 http://medscipublisher.com/index.php/ijccr 279 Strict monitoring after vaccination is particularly important for the early detection and handling of rare but dangerous adverse reactions, such as allergies. The Vaccine Adverse Event Reporting System (VAERS) and real-time medication safety monitoring tools have significantly enhanced the level of vaccine safety monitoring in the population. With the application of advanced data integration, machine learning and rapid analysis technologies, the accuracy and timeliness of discovering security risk signals are both improving. However, there are still problems such as incomplete reports, inaccurate reports, and inadequate integration of multi-source data. Therefore, it is necessary to continuously improve the monitoring system, enhance data transparency and sharing, and conduct rigorous statistical analysis. Special attention should be paid to people with autoimmune diseases or known allergic risks, and potential dangers should be detected and defused in a timely manner. Although severe vaccine allergic reactions are particularly rare, a lot of evidence shows that the health benefits brought by vaccination far outweigh the possible risks for both individuals and groups. Vaccines remain one of the most effective means of preventing infectious diseases and their complications. A standardized vaccination process-including comprehensive pre-vaccination assessment, emergency preparedness for acute adverse reactions and continuous monitoring-can minimize adverse situations to the greatest extent and maintain public trust in vaccines. Overall, adopting a balanced strategy: emphasizing both the significant benefits of vaccines and their rare risks, while continuously conducting publicity and education for medical staff and the public, and applying scientifically based prevention and treatment methods, is the key to maintaining a high vaccination rate and safeguarding global health. Acknowledgments The author extends sincere thanks to two anonymous peer reviewers for their feedback on the manuscript. Conflict of Interest Disclosure The author affirms that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. References Alhumaid S., Mutair A., Alawi Z., Rabaan A., Tirupathi R., Alomari M., Alshakhes A., Alshawi A., Ahmed G., Almusabeh H., Alghareeb T., Alghuwainem A., Alsulaiman Z., Alabdulmuhsin M., AlBuwaidi E., Dukhi A., Mufti H., Al-Qahtani M., Dhama K., Al-Tawfiq J., and Al-Omari A., 2021, Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis, Allergy Asthma and Clinical Immunology, 17(1): 109. https://doi.org/10.1186/s13223-021-00613-7 Aytekin E., Sekerel B., and Şahiner Ü., 2021, Allergic reactions during childhood vaccination and management, The Turkish Journal of Pediatrics, 63(6): 941-954. https://doi.org/10.24953/turkjped.2021.06.001 Barta B., Radovits T., Dobos A., Kozma G., Mészáros T., Berényi P., Facskó R., Merkely B., and Szebeni J., 2023, The COVID-19 mRNA vaccine Comirnaty induces anaphylactic shock in an anti-PEG hyperimmune large animal model, European Heart Journal, (2023): 2023-05. https://doi.org/10.1093/eurheartj/ehad655.3291 Barth I., Weisser K., Gaston-Tischberger D., Mahler V., and Keller-Stanislawski B., 2023, Anaphylactic reactions after COVID-19 vaccination in Germany, Allergologie Select, 7: 90-100. https://doi.org/10.5414/alx02374e Bellomo R., Gallenga C., Caraffa A., Teté G., Ronconi G., and Conti P., 2021, Anaphylaxis is a rare reaction in COVID-19 vaccination, Journal of Biological Regulators and Homeostatic Agents, 35(3): 839-842. https://doi.org/10.23812/bellomo_edit_3_21 Bian S., Li L., Wang Z., Cui L., Xu Y., Guan K., and Zhao B., 2022, Allergic reactions after the administration of COVID-19 vaccines, Frontiers in Public Health, 10: 878081. https://doi.org/10.3389/fpubh.2022.878081 Bohlke K., Davis R., Marcy S., Braun M., Destefano F., Black S., Mullooly J., and Thompson R., 2003, Risk of anaphylaxis after vaccination of children and adolescents, Pediatrics, 112(4): 815-820. https://doi.org/10.1542/peds.112.4.815 Boufidou F., Hatziantoniou S., Theodoridou K., Maltezou H., Vasileiou K., Anastassopoulou C., Medić S., and Tsakris A., 2023, Anaphylactic reactions to COVID-19 vaccines: an updated assessment based on pharmacovigilance data, Vaccines, 11(3): 613. https://doi.org/10.3390/vaccines11030613 Brandão L., Tuyama M., De Carvalho F., Da Silva Santos A., Lemos A., Da Costa M., Mesquita E., Cerbino-Neto J., Varela M., Brasil P., and Rondon A., 2023, Overdiagnosis of vaccine allergy: skin testing and challenge at a public specialized unit (CRIE) in Rio de Janeiro Brazil, The Journal of Allergy and Clinical Immunology: Global, 2(3): 100101.
RkJQdWJsaXNoZXIy MjQ4ODYzNA==